<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMOXICILLIN AND CLAVULANATE POTASSIUM- amoxicillin and clavulanate potassium tablet, chewable </strong><br>A-S Medication Solutions LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">HIGHLIGHTS OF PRESCRIBING INFORMATION<br>These highlights do not include all the information needed to use Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and  Amoxicillin and Clavulanate Potassium Tablets USP (Chewable)  safely and effectively. See full prescribing information for Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (Chewable).<br>AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, AMOXICILLIN AND CLAVULANATE POTASSIUM FOR ORAL SUSPENSION USP, and AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP (CHEWABLE) for oral use                                               Initial U.S. Approval: 1984<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets, amoxicillin and clavulanate potassium for oral suspension, and  amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium tablets, amoxicillin and clavulanate potassium for oral suspension, and  amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Amoxicillin/clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for treatment of the following:  </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> (<a href="#i4i_section_id_c9dba49f-7d24-43d1-9b68-56641a9a59be">1.1</a>)  </p>
<p class="Highlighta">Acute bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (<a href="#i4i_section_id_a13c3472-ca88-4a78-b86c-db2993db349b">1.2</a>)  </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (<a href="#i4i_section_id_4cbe7fed-6bfc-44a0-8314-0e33bbfe8324">1.3</a>)  </p>
<p class="Highlighta">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_f9195a41-fcbf-4d4e-8a68-13213c3ce203">1.4</a>)  </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> (<a href="#i4i_section_id_c42ee400-4dec-48fc-a84b-f15d634f6a93">1.5</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adults and Pediatric Patients &gt; 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours. (<a href="#i4i_section_id_6e9a303e-7f5b-458d-b7f0-c7e719c9276c">2.1</a>, <a href="#i4i_section_id_b0073bfa-b1bb-46fd-b7ce-094275a05d60">2.2</a>) </li>
<li>Pediatric Patients Aged 12 Weeks (3 Months) and Older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. (<a href="#i4i_section_id_b0073bfa-b1bb-46fd-b7ce-094275a05d60">2.2</a>) </li>
<li>Neonates and Infants &lt; 12 Weeks of Age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. (<a href="#i4i_section_id_b0073bfa-b1bb-46fd-b7ce-094275a05d60">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Formulations and amoxicillin/clavulanate content are: </p>
<p class="Highlighta">Tablets: 500 mg/125 mg and 875 mg/125 mg (<a href="#i4i_dosage_form_strength_id_cd5edaf0-1e80-44fb-acdd-a45bfe1348a5">3</a>) </p>
<p class="Highlighta">Powder for Oral Suspension: 200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL (<a href="#i4i_dosage_form_strength_id_cd5edaf0-1e80-44fb-acdd-a45bfe1348a5">3</a>) </p>
<p class="Highlighta">Tablets (Chewable): 200 mg/28.5 mg and 400 mg/57 mg (<a href="#i4i_dosage_form_strength_id_cd5edaf0-1e80-44fb-acdd-a45bfe1348a5">3</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to amoxicillin/clavulanate potassium or to other beta-lactams (e.g., penicillins or cephalosporins) (<a href="#i4i_contraindications_id_ad233a8d-69ae-4b2d-8e87-ed2524ffc3a8">4</a>) </li>
<li>History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with amoxicillin/clavulanate potassium. (<a href="#i4i_contraindications_id_ad233a8d-69ae-4b2d-8e87-ed2524ffc3a8">4</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Serious (including fatal) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>: Discontinue amoxicillin/clavulanate potassium if a reaction occurs. (<a href="#i4i_section_id_1bd284c3-a7e5-4a45-aad5-406cdb5b830c">5.1</a>) </li>
<li>Hepatic dysfunction and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>: Discontinue if signs/symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur. Monitor liver function tests in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_f5c9c8a0-27b7-4a55-81d3-c8bd4c0cd238">5.2</a>) </li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD): Evaluate patients if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#i4i_section_id_b304de08-20f9-4706-856f-e422737f37b7">5.3</a>) </li>
<li>Patients with mononucleosis who receive amoxicillin/clavulanate potassium develop <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Avoid amoxicillin/clavulanate potassium use in these patients. (<a href="#i4i_section_id_3e377bdd-3bfc-46dd-b939-28093eb4d6ed">5.4</a>) </li>
<li>Overgrowth: The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with fungal or bacterial pathogens should be considered during therapy. (<a href="#i4i_section_id_837933b1-8522-482a-93ed-935f1f4e0f97">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most frequently reported adverse effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%) (<a href="#i4i_section_id_f589126c-b9f7-41d2-9674-6f751b5d8f09">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Coadministration with probenecid is not recommended. (<a href="#i4i_section_id_777aeb9b-868e-4869-a214-9d0c3de3a052">7.1</a>)</li>
<li>Concomitant use of amoxicillin/clavulanate potassium and oral anticoagulants may increase the prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. (<a href="#i4i_section_id_479ffacd-6dcd-455e-808a-0174f627a53b">7.2</a>) </li>
<li>Coadministration with allopurinol increases the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#i4i_section_id_482fe10b-ca8b-4680-a257-aac7ba6cc523">7.3</a>) </li>
<li>Amoxicillin/clavulanate potassium may reduce efficacy of oral contraceptives. (<a href="#i4i_section_id_73a9fb18-b3d6-4887-a039-3f63766fee9b">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pediatric Use: Modify dose in patients 12 weeks or younger. (<a href="#i4i_pediatric_use_id_ac6900c0-211b-4fdf-92cb-43caa4241178">8.4</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>; Dosage adjustment is recommended for severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR&lt; 30mL/min). (<a href="#i4i_section_id_ee13b433-3711-4e5b-9546-4af5f4411214">2.3</a>, <a href="#i4i_section_id_40c5e02c-cd80-4a49-8bcb-6e833e5c4ede">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> </a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Limitations of Use </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Directions for Mixing Oral Suspension </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span>/Hepatic Dysfunction </a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatic Dysfunction</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="Italics">Clostridium Difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (CDAD) </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin Rash</span> in Patients With Mononucleosis </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Potential for Microbial Overgrowth </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Phenylketonurics </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Development of Drug-Resistant Bacteria </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Probenecid </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Oral Anticoagulants </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Allopurinol </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Oral Contraceptives </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Effects on Laboratory Tests </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Lower Respiratory Tract and Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Pediatric Patients </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin/clavulanate potassium and other antibacterial drugs, amoxicillin/clavulanate potassium should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. </p>
<p>Amoxicillin/clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible isolates of the designated bacteria in the conditions listed below: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span> </h2>
<p class="First">– caused by beta-lactamase–producing isolates of <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Moraxella catarrhalis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>1.2 Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> </h2>
<p class="First">– caused by beta-lactamase–producing isolates of <span class="Italics">H. influenzae </span>and <span class="Italics">M. catarrhalis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </h2>
<p class="First">– caused by beta-lactamase–producing isolates of <span class="Italics">H. influenzae </span>and <span class="Italics">M. catarrhalis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.4"></a><p></p>
<h2>1.4 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </h2>
<p class="First">– caused by beta-lactamase–producing isolates of <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">Escherichia coli</span>, and <span class="Italics">Klebsiella </span>species. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.5"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </h2>
<p class="First">– caused by beta-lactamase–producing isolates of <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella </span>species, and <span class="Italics">Enterobacter </span>species. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.6"></a><p></p>
<h2>1.6 Limitations of Use </h2>
<p class="First">– When susceptibility test results show susceptibility to amoxicillin, USP, indicating no beta-lactamase production, amoxicillin/clavulanate potassium should not be used. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Amoxicillin/clavulanate potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when amoxicillin/clavulanate potassium is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, amoxicillin/clavulanate potassium should be taken at the start of a meal.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 Adults</h2>
<p class="First">The usual adult dose is one 500-mg tablet of amoxicillin/clavulanate potassium every 12 hours or one 250 mg tablet of amoxicillin/clavulanate potassium every 8 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the respiratory tract, the dose should be one 875 mg tablet of amoxicillin/clavulanate potassium every 12 hours or one 500 mg tablet of amoxicillin/clavulanate potassium every 8 hours. Adults who have difficulty swallowing may be given the 125 mg/5 mL or 250 mg/5 mL suspension in place of the 500 mg tablet. The 200 mg/5 mL suspension or the 400 mg/5 mL suspension may be used in place of the 875 mg tablet. </p>
<p>Two 250 mg tablets of amoxicillin/clavulanate potassium should <span class="Italics">not </span>be substituted for one 500 mg tablet of amoxicillin/clavulanate potassium. Since both the 250 mg and 500 mg tablets of amoxicillin/clavulanate potassium contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg tablets are not equivalent to one 500 mg tablet of amoxicillin/clavulanate potassium. </p>
<p>The 250 mg tablet of amoxicillin/clavulanate potassium and the 250 mg chewable tablet should <span class="Italics">not </span>be substituted for each other, as they are not interchangeable. The 250 mg tablet of amoxicillin/clavulanate potassium and the 250 mg chewable tablet do not contain the same amount of clavulanic acid (as the potassium salt). The 250 mg tablet of amoxicillin/clavulanate potassium contains 125 mg of clavulanic acid, whereas the 250 mg chewable tablet contains 62.5 mg of clavulanic acid. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First">Based on the amoxicillin component, amoxicillin/clavulanate potassium should be dosed as follows: </p>
<p><span class="Underline">Neonates and Infants Aged &lt; 12 Weeks (&lt; 3 Months): </span>The recommended dose of amoxicillin/clavulanate potassium is 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Experience with the 200 mg/5 mL formulation in this age group is limited, and thus, use of the 125 mg/5 mL oral suspension is recommended. </p>
<p><span class="Underline">Patients Aged 12 Weeks (3 Months) and Older: </span>See dosing regimens provided in <span class="Bold">Table 1</span>. The every 12 hour regimen is recommended as it is associated with significantly less <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Italics">[see Clinical Studies (<a href="#i4i_section_id_8a85f021-73fa-4cc0-b9f6-7b2ea9ffb501">14.2</a>)]</span>. However, the every 12 hour suspension (200 mg/5 mL and 400 mg/5 mL) and chewable tablets (200 mg and 400 mg) contain aspartame and should not be used by phenylketonurics. <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_70b394a2-bcad-47ac-b6e3-7882ba58e733">5.6</a>)] </span></p>
<a name="id_48b32107-c614-4c1c-8513-5e4693c07baf"></a><table border="single" width="444">
<col width="27.7%">
<col width="36.5%">
<col width="35.7%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Each strength of suspension of amoxicillin/clavulanate potassium is available as a chewable tablet for use by older children.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Duration of therapy studied and recommended for acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 10 days.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><p class="First"><span class="Bold">Table 1: Dosing in Patients Aged 12 Weeks (3 Months) and Older </span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span> </span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">DOSING REGIMEN</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Every 12 hours</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Every 8 hours</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">200 mg/5 mL or 400 mg/5 mL oral suspension<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">125 mg/5 mL or 250 mg/5 mL oral suspension<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span>, and more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td class="Botrule Rrule" align="center" valign="top">45 mg/kg/day every 12 hours</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg/kg/day every 8 hours</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Less severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td class="Rrule" align="center" valign="middle">25 mg/kg/day every 12 hours</td>
<td class="Botrule Rrule" align="center" valign="middle">20 mg/kg/day every 8 hours</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Patients Weighing 40 kg or More: </span>Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations. </p>
<p>The 250 mg tablet of amoxicillin/clavulanate potassium should <span class="Italics">not </span>be used until the child weighs at least 40 kg, due to the different amoxicillin to clavulanic acid ratios in the 250 mg tablet of amoxicillin/clavulanate potassium (250/125) versus the 250 mg chewable tablet of amoxicillin/clavulanate potassium (250/62.5). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>2.3 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> do not generally require a reduction in dose unless the impairment is severe. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> patients with a glomerular filtration rate of &lt; 30 mL/min should not receive the 875 mg dose. Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. They should receive an additional dose both during and at the end of dialysis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>2.4 Directions for Mixing Oral Suspension </h2>
<p class="First">Prepare a suspension at time of dispensing as follows: Tap bottle until all the powder flows freely. Add approximately 2/3 of the total amount of water for reconstitution (see <span class="Bold">Table 2</span> below) and shake vigorously to suspend powder. Add remainder of the water and again shake vigorously. </p>
<a name="id_8ece630b-74f1-47b0-bd60-f5faf06281c3"></a><table border="single" width="447">
<col width="17.4%">
<col width="15.0%">
<col width="24.0%">
<col width="43.5%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First"><span class="Bold">Table 2: Amount of Water for Mixing Oral Suspension </span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Strength </span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Bottle Size</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Amount of Water for Reconstitution</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Contents of Each Teaspoonful (5 mL)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">200 mg/28.5 mg per 5 mL </td>
<td class="Botrule Rrule" align="center" valign="top">100 mL</td>
<td class="Botrule Rrule" align="center" valign="top">92 mL</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg amoxicillin and 28.5 mg of clavulanic acid as the potassium salt</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">400 mg/57 mg per 5 mL</td>
<td class="Rrule" align="center" valign="top">100 mL</td>
<td class="Rrule" align="center" valign="top">87 mL</td>
<td class="Botrule Rrule" align="center" valign="top">400 mg amoxicillin and 57 mg of clavulanic acid as the potassium salt</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Note:</span> Shake oral suspension well before using. Reconstituted suspension must be stored under refrigeration and discarded after 10 days.</p>
<p> </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold">Tablets</span></p>
<p>500 mg/125 mg Tablets:  White, oblong-shaped, biconvex, film-coated, unscored tablets, debossed 93 on one side and 2274 on the other side. Each tablet contains 500 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt. </p>
<p>875 mg/125 mg Tablets:  White, capsule-shaped, biconvex, film-coated, scored tablets, debossed 93 on one side and 22 scoreline 75 (22 │ 75) on the other side. Each tablet contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt. </p>
<p><span class="Bold">Powder for Oral Suspension</span></p>
<p>200 mg/28.5 mg per 5 mL:  White to off-white, orange-raspberry flavored powder for oral suspension (each 5 mL of reconstituted suspension, when reconstituted according to directions on the container label, contains 200 mg amoxicillin and 28.5 mg of clavulanic acid as the potassium salt).  </p>
<p>400 mg/57 mg per 5 mL:  White to off-white, orange -raspberry flavored powder for oral suspension (each 5 mL of reconstituted suspension, when reconstituted according to directions on the container label, contains 400 mg amoxicillin and 57 mg of clavulanic acid as the potassium salt). </p>
<p><span class="Bold">Chewable Tablets</span></p>
<p>200 mg/28.5 mg Chewable Tablets:  Mottled pink, oval, biconvex, unscored tablets, debossed 93 on one side and 2270 on the other.</p>
<p>400 mg/57 mg Chewable Tablets:  Mottled pink, oval, biconvex, unscored tablets, debossed 93 on one side and 2272 on the other.</p>
<p>The 250 mg tablet of amoxicillin/clavulanate potassium and the 250 mg chewable tablet should NOT be substituted for each other, as they are not interchangeable and the 250 mg tablet should not be used in children weighing less than 40 kg. The 250 mg tablet of amoxicillin/clavulanate potassium and the 250 mg chewable tablet do not contain the same amount of clavulanic acid. The 250 mg tablet of amoxicillin/clavulanate potassium contains 125 mg of clavulanic acid whereas the 250 mg chewable tablet contains 62.5 mg of clavulanic acid. </p>
<p>Two 250 mg tablets of amoxicillin/clavulanate potassium should NOT be substituted for one 500 mg tablet of amoxicillin/clavulanate potassium. Since both the 250 mg and 500 mg tablets of amoxicillin/clavulanate potassium contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg tablets of amoxicillin/clavulanate potassium are not equivalent to one 500 mg tablet of amoxicillin/clavulanate potassium.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>4.1 Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </h2>
<p class="First">Amoxicillin/clavulanate potassium is contraindicated in patients with a history of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to amoxicillin, clavulanate or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span>/Hepatic Dysfunction </h2>
<p class="First">Amoxicillin/clavulanate potassium is contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with amoxicillin/clavulanate potassium. </p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including amoxicillin/clavulanate potassium. These reactions are more likely to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or a history of sensitivity to multiple allergens. Before initiating therapy with amoxicillin/clavulanate potassium, careful inquiry should be made regarding previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, or other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, amoxicillin/clavulanate potassium should be discontinued and appropriate therapy instituted. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Hepatic Dysfunction</h2>
<p class="First">Hepatic dysfunction, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> has been associated with the use of amoxicillin/clavulanate potassium. Hepatic toxicity is usually reversible; however, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported. Hepatic function should be monitored at regular intervals in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="Italics">Clostridium Difficile </span>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (CDAD) </h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin/clavulanate potassium, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin Rash</span> in Patients With Mononucleosis </h2>
<p class="First">A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus, amoxicillin/clavulanate potassium should not be administered to patients with mononucleosis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5 Potential for Microbial Overgrowth </h2>
<p class="First">The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with fungal or bacterial pathogens should be considered during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, amoxicillin/clavulanate potassium should be discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6 Phenylketonurics </h2>
<p class="First">Amoxicillin/clavulanate potassium chewable tablets and amoxicillin/clavulanate potassium powder for oral suspension contain aspartame which contains phenylalanine. Each 200 mg chewable tablet of amoxicillin/clavulanate potassium contains 3.4 mg phenylalanine.  Each 400 mg chewable tablet contains 6.7 mg phenylalanine.  Each 5 mL of the 200 mg/28.5 mg per 5 mL oral suspension contains 0.67 mg phenylalanine. Each 5 mL of the 400 mg/57 mg per 5 mL oral suspension contains 1.12 mg phenylalanine.  The other formulations of amoxicillin/clavulanate potassium do not contain phenylalanine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>5.7 Development of Drug-Resistant Bacteria </h2>
<p class="First">Prescribing amoxicillin/clavulanate potassium in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient, and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following are discussed in more detail in other sections of the labeling: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_1bd284c3-a7e5-4a45-aad5-406cdb5b830c">5.1</a>)] </span>
</li>
<li>Hepatic Dysfunction <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_f5c9c8a0-27b7-4a55-81d3-c8bd4c0cd238">5.2</a>)] </span>
</li>
<li>CDAD <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_b304de08-20f9-4706-856f-e422737f37b7">5.3</a>)] </span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>The most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%). Less than 3% of patients discontinued therapy because of drug-related adverse reactions. The overall incidence of adverse reactions, and in particular <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, increased with the higher recommended dose. Other less frequently reported adverse reactions (&lt; 1%) include: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. </p>
<p>In pediatric patients (aged 2 months to 12 years), 1 U.S./Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of amoxicillin/clavulanate potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of amoxicillin/clavulanate potassium for 10 days in the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and diaper area <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="Italics">[See Clinical Studies (<a href="#i4i_section_id_8a85f021-73fa-4cc0-b9f6-7b2ea9ffb501">14.2</a>)] </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of amoxicillin/clavulanate potassium. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin/clavulanate potassium. </p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, black “hairy? tongue, <span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">mucocutaneous candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment. <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_b304de08-20f9-4706-856f-e422737f37b7">5.3</a>)] </span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, serum sickness–like reactions (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and frequently <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span>, and cases of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported. <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_1bd284c3-a7e5-4a45-aad5-406cdb5b830c">5.1</a>)] </span></p>
<p><span class="Bold">Liver: </span>Hepatic dysfunction, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with amoxicillin/clavulanate potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported. <span class="Italics">[see Contraindications (<a href="#i4i_section_id_fcf58635-a2cd-4a59-aa50-be7ecfebad09">4.2</a>), Warnings and Precautions (<a href="#i4i_section_id_f5c9c8a0-27b7-4a55-81d3-c8bd4c0cd238">5.2</a>)] </span></p>
<p><span class="Bold">Renal: </span>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> have been reported. <span class="Italics">[see Overdosage (<a href="#i4i_overdosage_id_53fc4474-c90b-4ae4-a9d9-ec90af32f563">10</a>)] </span></p>
<p><span class="Bold">Hemic and Lymphatic Systems: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena. <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocytosis</span> was noted in less than 1% of the patients treated with amoxicillin/clavulanate potassium. There have been reports of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving amoxicillin/clavulanate potassium and anticoagulant therapy concomitantly. <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_479ffacd-6dcd-455e-808a-0174f627a53b">7.2</a>)] </span></p>
<p><span class="Bold">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> have been reported.</p>
<p><span class="Bold">Miscellaneous: </span><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Probenecid </h2>
<p class="First">Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Concurrent use with amoxicillin/clavulanate potassium may result in increased and prolonged blood concentrations of amoxicillin. Coadministration of probenecid is not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 Oral Anticoagulants </h2>
<p class="First">Abnormal prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently with amoxicillin/clavulanate potassium. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 Allopurinol </h2>
<p class="First">The concurrent administration of allopurinol and amoxicillin increases the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>7.4 Oral Contraceptives </h2>
<p class="First">Amoxicillin/clavulanate potassium may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>7.5 Effects on Laboratory Tests </h2>
<p class="First">High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST<span class="Sup">®</span>, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin/clavulanate potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. </p>
<p>Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects</span></p>
<p><span class="Underline">Pregnancy category B</span></p>
<p>Reproduction studies performed in pregnant rats and mice given amoxicillin/clavulanate potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to amoxicillin/clavulanate potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Oral ampicillin-class antibiotics are poorly absorbed during labor. It is not known whether use of amoxicillin/clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Amoxicillin has been shown to be excreted in human milk. Amoxicillin/clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin/clavulanate potassium is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of amoxicillin/clavulanate potassium powder for oral suspension and chewable tablets have been established in pediatric patients. Use of amoxicillin/clavulanate potassium in pediatric patients is supported by evidence from studies of amoxicillin/clavulanate potassium tablets in adults with additional data from a study of amoxicillin/clavulanate potassium powder for oral suspension in pediatric patients aged 2 months to 12 years with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_8a85f021-73fa-4cc0-b9f6-7b2ea9ffb501">14.2</a>)</span>] </p>
<p>Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of amoxicillin/clavulanate potassium should be modified in pediatric patients aged &lt; 12 weeks (&lt; 3 months). [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_b0073bfa-b1bb-46fd-b7ce-094275a05d60">2.2</a>)</span>] </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 3,119 patients in an analysis of clinical studies of amoxicillin/clavulanate potassium, 32% were ≥ 65 years old, and 14% were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>8.6 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt; 30 mL/min). See<span class="Italics"> Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#i4i_section_id_ee13b433-3711-4e5b-9546-4af5f4411214">2.3</a>)</span> for specific recommendations in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms<span class="Sup">1</span>. </p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been reported in patients after overdosage with amoxicillin/clavulanate potassium. </p>
<p><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been reported after amoxicillin/clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to reduce the risk of amoxicillin/clavulanate potassium <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of amoxicillin/clavulanate potassium. Amoxicillin/clavulanate potassium may be removed from circulation by hemodialysis. [see <span class="Italics">Dosage and Administration (<a href="#i4i_section_id_ee13b433-3711-4e5b-9546-4af5f4411214">2.3</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Amoxicillin and clavulanate potassium is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin, USP and the β-lactamase inhibitor, clavulanate potassium, USP (the potassium salt of clavulanic acid). Amoxicillin, USP is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Chemically, amoxicillin, USP is (<span class="Italics">2S</span>,<span class="Italics">5R</span>,<span class="Italics">6R</span>)-6-[(<span class="Italics">R</span>)-(-)-2-Amino-2-(<span class="Italics">p</span>-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and has the following structural formula:</p>
<div class="Figure"><img alt="amoxicillin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7383df90-6980-4e3b-bcbe-0675c1d26565&amp;name=7de36c3e-b7aa-4a92-b32c-17386e91f4e3-01.jpg"></div>
<p>C<span class="Sub">16</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S•3H<span class="Sub">2</span>O          M.W. 419.46</p>
<p>Clavulanic acid is produced by the fermentation of <span class="Italics">Streptomyces clavuligerus. </span>It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to penicillins and cephalosporins. Chemically, clavulanate potassium, USP is potassium (<span class="Italics">Z</span>)-(2<span class="Italics">R</span>,5<span class="Italics">R</span>)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and has the following structural formula:</p>
<div class="Figure"><img alt="clavulanic acid structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7383df90-6980-4e3b-bcbe-0675c1d26565&amp;name=7de36c3e-b7aa-4a92-b32c-17386e91f4e3-02.jpg"></div>
<p>C<span class="Sub">8</span>H<span class="Sub">8</span>KNO<span class="Sub">5</span>          M.W. 237.25</p>
<p><span class="Bold">Amoxicillin and Clavulanate Potassium Tablets USP</span></p>
<p>Each tablet contains 500 mg or 875 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. Each Amoxicillin and Clavulanate Potassium Tablet USP contains 0.63 mEq potassium.</p>
<p>Inactive Ingredients:  colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate, titanium dioxide, and triacetin.</p>
<p><span class="Bold">Amoxicillin and Clavulanate Potassium for Oral Suspension USP</span></p>
<p>After reconstitution each teaspoonful (5 mL) of suspension will contain 200 mg amoxicillin, USP as the trihydrate and 28.5 mg clavulanic acid as the potassium salt or 400 mg amoxicillin, USP as the trihydrate and 57 mg clavulanic acid as the potassium salt. Each 5 mL of reconstituted Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5 mL contains 0.14 mEq potassium. Each 5 mL of reconstituted Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 400 mg/57 mg per 5 mL contains 0.29 mEq of potassium.</p>
<p>Inactive Ingredients:  Powder for oral suspension:  artificial raspberry powder, aspartame<span class="Sup">*</span>, citric acid, colloidal silicon dioxide, mannitol, hypromellose, natural orange flavor, sodium citrate, sodium saccharin and xanthan gum.</p>
<p><span class="Sup">* </span>See <span class="Italics">Warnings and Precautions (5.6)</span>.</p>
<p><span class="Bold">Amoxicillin and Clavulanate Potassium Tablets USP (Chewable)</span></p>
<p>Each chewable tablet contains 200 mg amoxicillin, USP as the trihydrate and 28.5 mg clavulanic acid as the potassium salt or contains 400 mg amoxicillin, USP as the trihydrate and 57 mg clavulanic acid as the potassium salt. Each Amoxicillin and Clavulanate Potassium Tablet USP, (Chewable) 200 mg/28.5 mg contains 0.14 mEq potassium. Each Amoxicillin and Clavulanate Potassium Tablet USP, (Chewable) 400 mg/57 mg contains 0.29 mEq potassium.</p>
<p>Inactive Ingredients:  aspartame<span class="Sup">*</span>, colloidal silicon dioxide, FD&amp;C Red #40 lake, magnesium stearate, mannitol, microcrystalline cellulose, SA84 artificial ripe banana flavor, and artificial cherry flavor powder.</p>
<p><span class="Sup">*</span> See <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_70b394a2-bcad-47ac-b6e3-7882ba58e733">5.6</a>)</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Amoxicillin/clavulanate potassium is an antibacterial drug. <span class="Italics">[see Microbiology <a href="#i4i_section_id_85630494-4f38-4135-9986-d01314caadb2">12.4</a>] </span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of amoxicillin and clavulanate potassium tablets are shown in <span class="Bold">Table 3</span> and following administration of amoxicillin and clavulanate potassium powder for oral suspension and chewable tablets are shown in <span class="Bold">Table 4</span>. </p>
<a name="id_de538a16-807b-4e28-b474-ac0838118e0e"></a><table border="single" width="437">
<col width="34.3%">
<col width="17.1%">
<col width="16.5%">
<col width="16.5%">
<col width="15.7%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Mean (± standard deviation) values of 14 normal adults (N=15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Amoxicillin/clavulanate potassium administered at the start of a light meal.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5" valign="top"><p class="First"><span class="Bold">Table 3: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>With Amoxicillin and Clavulanate Potassium Tablets</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Dose and Regimen </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">C<span class="Sub">max</span> (mcg/mL)</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">AUC<span class="Sub">0 to 24</span> (mcg*h/mL)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Amoxicillin/Clavulanate Potassium </td>
<td class="Botrule Rrule" align="center" valign="top">Amoxicillin</td>
<td class="Botrule Rrule" align="center" valign="top">Clavulanate Potassium</td>
<td class="Botrule Rrule" align="center" valign="top">Amoxicillin</td>
<td class="Botrule Rrule" align="center" valign="top">Clavulanate Potassium</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">250/125 mg every 8 hours </td>
<td class="Botrule Rrule" align="center" valign="middle">3.3 ± 1.12</td>
<td class="Botrule Rrule" align="center" valign="middle">1.5 ± 0.70</td>
<td class="Botrule Rrule" align="center" valign="middle">26.7 ± 4.56</td>
<td class="Botrule Rrule" align="center" valign="middle">12.6 ± 3.25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">500/125 mg every 12 hours </td>
<td class="Botrule Rrule" align="center" valign="middle">6.5 ± 1.41</td>
<td class="Botrule Rrule" align="center" valign="middle">1.8 ± 0.61</td>
<td class="Botrule Rrule" align="center" valign="middle">33.4 ± 6.76</td>
<td class="Botrule Rrule" align="center" valign="middle">8.6 ± 1.95</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">500 125 mg every 8 hours </td>
<td class="Botrule Rrule" align="center" valign="middle">7.2 ± 2.26</td>
<td class="Botrule Rrule" align="center" valign="middle">2.4 ± 0.83</td>
<td class="Botrule Rrule" align="center" valign="middle">53.4 ± 8.87</td>
<td class="Botrule Rrule" align="center" valign="middle">15.7 ± 3.86</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">875/125 mg every 12 hours </td>
<td class="Rrule" align="center" valign="middle">11.6 ± 2.78</td>
<td class="Rrule" align="center" valign="middle">2.2 ± 0.99</td>
<td class="Rrule" align="center" valign="middle">53.5 ± 12.31</td>
<td class="Botrule Rrule" align="center" valign="middle">10.2 ± 3.04</td>
</tr>
</tbody>
</table>
<a name="id_022ff09b-617b-46b1-9ad8-cc1528e53f21"></a><table border="single" width="437">
<col width="34.3%">
<col width="17.1%">
<col width="16.5%">
<col width="16.5%">
<col width="15.7%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Mean (<span class="Underline">±</span> standard deviation) values of 28 normal adults.  Peak concentrations occurred approximately 1 hour after the dose.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Amoxicillin/clavulanate potassium administered at the start of a light meal.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5" valign="top"><p class="First"><span class="Bold">Table 4: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters <a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>With Amoxicillin and Clavulanate Potassium Powder for Oral Suspension and Chewable Tablets</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Dose </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">C<span class="Sub">max </span>(mcg/mL) </td>
<td class="Botrule Rrule" align="left" colspan="2" valign="bottom">AUC<span class="Sub">0 to 24</span> (mcg*h/mL) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Amoxicillin/Clavulanate Potassium </td>
<td class="Botrule Rrule" align="center" valign="top">Amoxicillin</td>
<td class="Botrule Rrule" align="center" valign="top">Clavulanate Potassium</td>
<td class="Botrule Rrule" align="center" valign="top">Amoxicillin</td>
<td class="Botrule Rrule" align="center" valign="top">Clavulanate Potassium</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">400/57 mg (5 mL of suspension) </td>
<td class="Botrule Rrule" align="center" valign="top">6.94 ± 1.24</td>
<td class="Botrule Rrule" align="center" valign="top">1.10 ± 0.42</td>
<td class="Botrule Rrule" align="center" valign="top">17.29 ± 2.28</td>
<td class="Botrule Rrule" align="center" valign="top">2.34 ± 0.94</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">400/57 mg (1 chewable tablet) </td>
<td class="Rrule" align="center" valign="top">6.67 ± 1.37</td>
<td class="Rrule" align="center" valign="top">1.03 ± 0.33</td>
<td class="Rrule" align="center" valign="top">17.24 ± 2.64</td>
<td class="Botrule Rrule" align="center" valign="top">2.17 ± 0.73</td>
</tr>
</tbody>
</table>
<p>Oral administration of 5 mL of 250 mg/5 mL suspension of amoxicillin/clavulanate potassium or the equivalent dose of 10 mL of 125 mg/5 mL suspension of amoxicillin/clavulanate potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of 250 mg/5 mL suspension of amoxicillin/clavulanate potassium or equivalent dose of 10 mL of 125 mg/5 mL suspension of amoxicillin/clavulanate potassium were administered to normal adults. One 250-mg chewable tablet of amoxicillin/clavulanate potassium or two 125 mg chewable tablets of amoxicillin/clavulanate potassium are equivalent to 5 mL of 250 mg/5 mL suspension of amoxicillin/clavulanate potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. </p>
<p>Amoxicillin serum concentrations achieved with amoxicillin/clavulanate potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8 hour dosing regimens of amoxicillin/clavulanate potassium in adults and children. </p>
<p><span class="Italics">Absorption</span></p>
<p>Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While amoxicillin/clavulanate potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when amoxicillin/clavulanate potassium was dosed at 30 and 150 minutes after the start of a high-fat breakfast. </p>
<p><span class="Italics">Distribution</span></p>
<p>Neither component in amoxicillin/clavulanate potassium is highly protein-bound; clavulanic acid is approximately 25% bound to human serum and amoxicillin approximately 18% bound. </p>
<p>Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid.</p>
<p>Two hours after oral administration of a single 35 mg/kg dose of suspension of amoxicillin/clavulanate potassium to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in <span class="product-label-link" type="condition" conceptid="4082782" conceptname="Fluid level behind tympanic membrane">middle ear effusions</span>. </p>
<p><span class="Italics">Metabolism and Excretion</span></p>
<p>The half-life of amoxicillin after the oral administration of amoxicillin/clavulanate potassium is 1.3 hours and that of clavulanic acid is 1 hour. </p>
<p>Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single 250 mg or 500 mg tablet of amoxicillin/clavulanate potassium. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology </h2>
<p class="First">Amoxicillin is a semisynthetic antibiotic with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. </p>
<p>The formulation of amoxicillin and clavulanic acid in amoxicillin/clavulanate potassium protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. </p>
<p>Amoxicillin/clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section. </p>
<p><span class="Underline">Gram-Positive Bacteria </span></p>
<p><span class="Italics">Staphylococcus aureus </span></p>
<p><span class="Underline">Gram-Negative Bacteria </span></p>
<p><span class="Italics">Enterobacter </span>species </p>
<p><span class="Italics">Escherichia coli </span></p>
<p><span class="Italics">Haemophilus influenzae </span></p>
<p><span class="Italics">Klebsiella </span>species </p>
<p><span class="Italics">Moraxella catarrhalis</span></p>
<p>The following in vitro data are available, <span class="Bold">but their clinical significance is unknown</span>. At least 90 percent of the following bacteria exhibit an in vitro <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for amoxicillin/clavulanic acid. However, the efficacy of amoxicillin/clavulanic acid in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria <span class="Bold">has not been</span> established in adequate and well-controlled clinical trials. </p>
<p><span class="Underline">Gram-Positive Bacteria </span></p>
<p><span class="Italics">Enterococcus faecalis </span></p>
<p><span class="Italics">Staphylococcus epidermidis </span></p>
<p><span class="Italics">Staphylococcus saprophyticus </span></p>
<p><span class="Italics">Streptococcus pneumoniae </span></p>
<p><span class="Italics">Streptococcus pyogenes </span></p>
<p>Viridans group <span class="Italics">Streptococcus </span></p>
<p><span class="Underline">Gram-Negative Bacteria </span></p>
<p><span class="Italics">Eikenella corrodens </span></p>
<p><span class="Italics">Proteus mirabilis </span></p>
<p><span class="Underline">Anaerobic Bacteria </span></p>
<p><span class="Italics">Bacteroides </span>species including <span class="Italics">Bacteroides fragilis </span></p>
<p><span class="Italics">Fusobacterium </span>species </p>
<p><span class="Italics">Peptostreptococcus </span>species </p>
<p><span class="Italics">Susceptibility Test Methods </span></p>
<p>When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<p><span class="Underline">Dilution Techniques </span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method<span class="Sup">2,3 </span>(broth and/or agar). The MIC values should be interpreted according to criteria provided in <span class="Bold">Table 5</span>. </p>
<p><span class="Underline">Diffusion Techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method<span class="Sup">3,4</span>. This procedure uses paper disks impregnated with 30 mcg amoxicillin/clavulanic acid (20 mcg amoxicillin plus 10 mcg clavulanic acid) to test the susceptibility of bacteria to amoxicillin/clavulanic acid. The disc diffusion interpretive criteria are provided in Table 5.</p>
<a name="id_127f316e-47bb-44a5-ad0b-fed4bc1af603"></a><table border="single" width="456">
<col width="52.1%">
<col width="22.7%">
<col width="25.3%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><p class="First"><span class="Bold">Table 5: Susceptibility Test Interpretive Criteria for Amoxicillin Clavulanic Acid</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL) </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Disk Diffusion (Zone Diameters in mm)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Pathogen </td>
<td class="Botrule Rrule" align="left" valign="top">S         I           R </td>
<td class="Botrule Rrule" align="left" valign="top">S           I           R </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Italics">Enterobacteriaceae</span></td>
<td class="Botrule Rrule" align="left" valign="top">8/4    16/8     32/16 </td>
<td class="Botrule Rrule" align="left" valign="top">&gt; 18  14-17    &lt; 13  </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Staphylococcus aureus</span>
</td>
<td class="Rrule" align="left" valign="top">4/2      -          8/4 </td>
<td class="Botrule Rrule" align="left" valign="top">&gt; 20     -         &lt; 19</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test<span class="Sup">2,3,4</span>. Standard amoxicillin/clavulanic acid powder should provide the following range of MIC values noted in Table 6 for the diffusion technique using the 30 mcg amoxicillin/clavulanic acid (20 mcg amoxicillin plus 10 mcg clavulanic acid) disk, the criteria in Table 6 should be achieved.</p>
<a name="id_20e55873-b57e-4e29-a7b5-8ca53df07f1f"></a><table border="single" width="482">
<col width="50.5%">
<col width="24.7%">
<col width="24.8%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><p class="First"><span class="Bold">Table 6: Acceptable Quality Control Ranges for Amoxicillin/Clavulanic Acid</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span> </td>
<td class="Botrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> (mcg/mL) </td>
<td class="Botrule Rrule" align="center" valign="top">Disk Diffusion (Zone Diameter in mm) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Escherichia coli </span>ATCC 25922 </td>
<td class="Botrule Rrule" align="center" valign="top">2/1 to 8/4 </td>
<td class="Botrule Rrule" align="center" valign="top">18 to 24 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Escherichia coli </span>ATCC 35218 </td>
<td class="Botrule Rrule" align="center" valign="top">4/2 to 16/8 </td>
<td class="Botrule Rrule" align="center" valign="top">17 to 22 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49247 </td>
<td class="Botrule Rrule" align="center" valign="top">2/1 to 16/8 </td>
<td class="Botrule Rrule" align="center" valign="top">15 to 23 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Staphylococcus aureus </span>ATCC 29213 </td>
<td class="Botrule Rrule" align="center" valign="top">0.12/0.06 to 0.5/0.25 </td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Italics">Staphylococcus aureus </span>ATCC 29523 </td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="top">28 to 36 </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential. </p>
<p>Amoxicillin/clavulanate potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin/clavulanate potassium was weakly positive in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin/clavulanate potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. </p>
<p>Amoxicillin/clavulanate potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Lower Respiratory Tract and Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </h2>
<p class="First">Data from 2 pivotal trials in 1,191 patients treated for either <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> or complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> compared a regimen of 875 mg tablets of amoxicillin/clavulanate potassium every 12 hours to 500 mg tablets of amoxicillin/clavulanate potassium dosed every 8 hours (584 and 607 patients, respectively). Comparable efficacy was demonstrated between the every 12 hours and every 8 hours dosing regimens. There was no significant difference in the percentage of adverse events in each group. The most frequently reported adverse event was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; incidence rates were similar for the 875 mg every 12 hours and 500 mg every 8 hours dosing regimens (15% and 14%, respectively); however, there was a statistically significant difference (p &lt; 0.05) in rates of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or withdrawals with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> between the regimens: 1% for 875 mg every 12 hours regimen versus 2% for the 500 mg every 8 hours regimen. </p>
<p>In one of these pivotal trials, patients with either <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> (n = 361) or a complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (i.e., patients with abnormalities of the urinary tract that predispose to relapse of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span> following eradication, n = 268) were randomized (1:1) to receive either 875 mg tablets of amoxicillin/clavulanate potassium every 12 hours (n = 308) or 500 mg tablets of amoxicillin/clavulanate potassium every 8 hours (n = 321).</p>
<p>The number of bacteriologically evaluable patients was comparable between the two dosing regimens. Amoxicillin/clavulanate potassium produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at one of the follow-up visits (5 to 9 days post-therapy) and at a late post-therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in <span class="Bold">Table 7</span>.</p>
<p><span class="Bold">Table 7: Bacteriologic Efficacy Rates for Amoxicillin/Clavulanate Potassium</span></p>
<a name="id_98e94796-3434-4d1c-bb9b-9a72d9b6817a"></a><table border="single" width="480">
<col width="33.4%">
<col width="33.2%">
<col width="33.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Time Post Therapy </span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">875 mg Every 12 Hours % (n) </span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">500 mg Every 8 Hours % (n) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">2 to 4 days </td>
<td class="Botrule Rrule" align="center" valign="middle">81% (58) </td>
<td class="Botrule Rrule" align="center" valign="middle">80% (54) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">5 to 9 days </td>
<td class="Botrule Rrule" align="center" valign="middle">58% (41) </td>
<td class="Botrule Rrule" align="center" valign="middle">52% (52) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">2 to 4 weeks </td>
<td class="Rrule" align="center" valign="middle">52% (101) </td>
<td class="Botrule Rrule" align="center" valign="middle">55% (104) </td>
</tr>
</tbody>
</table>
<p> </p>
<p>As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or withdrawals with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> between the regimens. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Pediatric Patients </h2>
<p class="First">One U.S./Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of amoxicillin/clavulanate potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of amoxicillin/clavulanate potassium for 10 days in the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., ≥ 84%) per treatment group. <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span>-specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow-up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow-up visit (defined as 22 to 28 days post-completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n = 265) and 82% (n = 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. At follow-up, 67% (n = 249) and 69% (n = 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. </p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was defined as either: (a) 3 or more watery or 4 or more loose/watery stools in 1 day; OR (b) 2 watery stools per day or 3 loose/watery stools per day for 2 consecutive days. The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was significantly lower in patients who received the every 12 hours regimen compared to patients who received the every 8 hours regimen (14% and 34%, respectively). In addition, the number of patients with either severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or who were withdrawn with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was significantly lower in the every 12 hours treatment group (3% and 8% for the every 12 hours/10 day and every 8 hours/10 day, respectively). In the every 12 hours treatment group, 3 patients (1%) were withdrawn with an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, while 1 patient in the every 8 hours group was withdrawn for this reason. The number of patients with a <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidal infection</span> of the diaper area was 4% and 6% for the every 12 hours and every 8 hours groups, respectively. </p>
<p>It is not known if the finding of a statistically significant reduction in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with the oral suspensions dosed every 12 hours, versus suspensions dosed every 8 hours, can be extrapolated to the chewable tablets. The presence of mannitol in the chewable tablets may contribute to a different <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> profile. The every 12 hour oral suspensions (200 mg/5 mL and 400 mg/5 mL) are sweetened with aspartame.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 8<span class="Sup">th </span>ed. CLSI Document M7-A9. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 19087, 2012. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standard for Antimicrobial Disk Susceptibility Tests;Approved Standard – 11<span class="Sup">th </span>ed. CLSI Document M2-A11. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 19087, 2012. </li>
<li>CLSI. Performance Standards for Antimicrobial Susceptibility Testing: 22<span class="Sup">nd</span> Informational Supplement. CLSI document M100-S22. CLSI, Wayne, PA, 2012.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Amoxicillin and Clavulanate Potassium Tablets USP</span></p>
<p>Amoxicillin and Clavulanate Potassium Tablets USP are supplied as follows:</p>
<p>500 mg/125 mg: White, oblong-shaped, biconvex, film-coated, unscored tablets, debossed 93 on one side and 2274 on the other side. Each tablet contains 500 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. They are available in bottles of 20 tablets.</p>
<p>875 mg/125 mg: White, capsule-shaped, biconvex, film-coated, scored tablets, debossed 93 on one side and 22 scoreline 75 (22 │ 75) on the other side. Each tablet contains 875 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. They are available in bottles of 20 tablets.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Advise patients to keep in a closed container.</p>
<p><span class="Bold">Amoxicillin and Clavulanate Potassium for Oral Suspension USP</span></p>
<p>Amoxicillin and Clavulanate Potassium for Oral Suspension USP is supplied as follows:</p>
<p>200 mg/28.5 mg per 5 mL: White to off-white powder – Each 5 mL of reconstituted orange-raspberry-flavored suspension contains 200 mg amoxicillin, USP and 28.5 mg clavulanic acid as the potassium salt. It is available in bottles of 100 mL.</p>
<p>400 mg/57 mg per 5 mL: White to off-white powder – Each 5 mL of reconstituted orange-raspberry-flavored suspension contains 400 mg amoxicillin, USP and 57 mg clavulanic acid as the potassium salt. It is available in bottles of 100 mL.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in original containers. Store reconstituted suspension under refrigeration. Discard unused suspension after 10 days.</p>
<p><span class="Bold">Amoxicillin and Clavulanate Potassium Tablets USP (Chewable)</span></p>
<p>Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) are supplied as follows:</p>
<p>200 mg/28.5 mg: Mottled pink, oval, biconvex, unscored tablets, debossed 93 on one side and 2270 on the other.  They are available in bottles of 20 tablets.</p>
<p>400 mg/57 mg:  Mottled pink, oval, biconvex, unscored tablets, debossed 93 on one side and 2272 on the other.  They are available in bottles of 20 tablets.</p>
<p>Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<p class="First">Patients should be informed that amoxicillin/clavulanate potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed. Each dose should be taken with a meal or snack to reduce the possibility of <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>. </p>
<p>Patients should be counseled that antibacterial drugs, including amoxicillin/clavulanate potassium, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When amoxicillin/clavulanate potassium is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin/clavulanate potassium or other antibacterial drugs in the future. </p>
<p>Counsel patients that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken their last dose of the antibacterial. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is severe or lasts more than 2 or 3 days, patients should contact their physician. </p>
<p>Patients should be advised to keep suspension refrigerated. Shake well before using. When dosing a child with the suspension (liquid) of amoxicillin/clavulanate potassium, use a dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper after each use. Bottles of suspension of amoxicillin/clavulanate potassium may contain more liquid than required. Follow your doctor’s instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine. </p>
<p>Patients should be aware that amoxicillin/clavulanate potassium contains a penicillin class drug product that can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in some individuals. </p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.</p>
<p>Manufactured In Canada By:</p>
<p><span class="Bold">TEVA CANADA LIMITED</span></p>
<p>Toronto, Canada M1B 2K9</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Iss. 2/2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-5638-0</span></p>
<p>Relabeled by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="5638-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7383df90-6980-4e3b-bcbe-0675c1d26565&amp;name=5638-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUM 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-5638(NDC:0093-2272)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMOXICILLIN</strong> (AMOXICILLIN ANHYDROUS) </td>
<td class="formItem">AMOXICILLIN ANHYDROUS</td>
<td class="formItem">400 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CLAVULANATE POTASSIUM</strong> (CLAVULANIC ACID) </td>
<td class="formItem">CLAVULANIC ACID</td>
<td class="formItem">57 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (mottled pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BANANA (banana and cherry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">93;2272</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-5638-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54569-5638-1</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065205</td>
<td class="formItem">02/10/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">relabel(54569-5638)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>184b7d98-815c-4aa7-83a3-d5f28104c734</div>
<div>Set id: 7383df90-6980-4e3b-bcbe-0675c1d26565</div>
<div>Version: 1</div>
<div>Effective Time: 20130620</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
